Medtide Inc. (HKG:3880)

Market Cap	3.18B
Revenue (ttm)	546.29M +34.3%
Net Income	121.20M +46.6%
EPS	0.97 +75.4%
Shares Out	141.80M
PE Ratio	23.14
Forward PE	13.85
Dividend	n/a
Ex-Dividend Date	n/a

Volume	85,600
Average Volume	104,835
Open	22.10
Previous Close	22.18
Day's Range	21.04 - 22.96
52-Week Range	21.04 - 41.72
Beta	n/a
RSI	42.30
Earnings Date	Mar 30, 2026

About Medtide

Medtide Inc., a contract research, development, and manufacturing company, provides early-stage discovery, preclinical research, clinical development, and commercial-stage production services. It offers peptide new chemical entity discovery synthesis, peptide chemistry, manufacturing, and control development and commercial manufacturing services. The company focuses on developing oral and/or injectable glucagon, such as peptide-1 (GLP-1) molecule products. Its research and development technology platform include OmniPeptSynth, PeptiConjuX, Pept...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2020
• Employees: 520
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 3880

Financial Performance

In 2024, Medtide's revenue was 442.23 million, an increase of 31.31% compared to the previous year's 336.77 million. Earnings were 59.17 million, an increase of 21.00%.

Financial numbers in CNY